Navigation Links
Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Date:1/31/2008

SAN MATEO, Calif., Jan. 31 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. today announced it has entered into manufacturing agreements with Albemarle Corporation and Patheon Inc. The agreements provide for the large-scale clinical production of Varespladib (A-002), which is expected to be necessary in preparation for Anthera's Phase III clinical trials and planned New Drug Application submission to the Food and Drug Administration. Varespladib is Anthera's oral drug candidate for the treatment of cardiovascular disease.

Anthera believes the agreements position the company to:

-- Secure a cost-effective, long-term supply of Varespladib active

pharmaceutical ingredient (API) and tablets.

-- Quickly scale current manufacturing efforts to meet production

requirements, potentially accelerating Varespladib's time-to-market.

-- Reduce manufacturing related risks to the Varespladib clinical program.

-- Ensure a cost-effective transition to registration and commercial

production.

Building on the work done by Anthera's licensor, Eli Lilly, Albemarle will be responsible for process optimization and manufacture of cGMP quantities of the API. Patheon will be responsible for finished tablet production. The agreement also provides an option for the commercial production of Varespladib in the future. Financial terms were not disclosed.

"These agreements with Albemarle and Patheon provide Anthera with key supply chain resources for the manufacture of Varespladib," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals. "We are pleased to have secured outstanding technical organizations with significant commercial expertise that will contribute to the future success of the Varespladib program."

"We're delighted that Anthera has selected Albemarle as its API manufacturing supplier for its next phase of development," said David Clary, Albemarle Division V
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
6. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
7. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
8. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
11. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014   Easy Breathe , the fastest ... announced that it now offers the revolutionary AirSense ... the first sleep apnea therapy devices with internal cellular ... to track and share real-time data on each user,s ... CPAP therapy.  In addition, the internal modem allows the ...
(Date:9/30/2014)... ORANGE , N.J. and NEW BRUNSWICK, N.J., Sept. 30, ... affiliation agreement that allows Kessler Foundation and New ... advance biomedical research, education and patient care programs ... president and chief executive officer of Kessler Foundation ... New Jersey Health Foundation. "The experience ...
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3
(Date:9/30/2014)... New York, NY (PRWEB) September 30, 2014 ... and falling demand have hampered growth in the ... Popular diets have caused consumers to moderate their ... growing consumer preferences for premium varieties shrunk the ... bread products. Successful operators proactively responded by introducing ...
(Date:9/30/2014)... been awarded a three-year $1.7 million grant from ... new imaging technologies and data analysis techniques that ... of neurons in the brain interact to process ... the precise interactions between millions of nerve cells ... alterations in these interactions that may be responsible ...
(Date:9/30/2014)... September 30, 2014 The American ... to help diabetics curb their sweet tooth, but the ... this September, suggests that zero-calorie sweeteners may actually ... diabetes. , The Weizmann Institute of Science in ... artificial sweeteners to mice, the mice developed glucose intolerance. ...
(Date:9/30/2014)... 2014 Regenerative Medicine Solutions (RMS) is ... in Nashville, Tennessee. RMS welcomes the launch of an ... expansion of a new treatment center for the Lung ... Apnea Institute to Nashville, the hope is to bring ... both diagnosed and undiagnosed. With Nashville being a hub ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Medicare should cover low-dose ... risk for the disease, a coalition of more than ... which includes the Lung Cancer Alliance, the Society of ... Cancer Society and the American Society of Clinical Oncology, ... the U.S. Centers for Medicare & Medicaid Services (CMS). ...
Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... Small Business Committee Leaders to Press for Affordable ... 24 In advance of tomorrow,s,Finance Committee hearing ... Kerry (D-Mass.) and Olympia J. Snowe (R-Maine), Chairman ... and Entrepreneurship,sent a letter to the leaders of ...
... from a Phase I/II clinical trial of a novel ... In 26 patients with advanced solid tumors, treatment with ... yielding plasma concentrations above the expected therapeutic threshold, says ... in Montreal, Canada. Thallion has produced and tested ...
... seven exceptionally talented and creative investigators in the early ... Health Science (NIEHS), part of the National Institutes of ... made under NIEHSs Outstanding New Environmental Sciences (ONES) program. ... of our efforts to help establish the careers of ...
... supports vitamins for respiratory health , , WEDNESDAY, Oct. 24 (HealthDay ... of drinks a day may help keep the doctor away, ... daily dose of alcohol helps the heart, this study suggests ... for smokers. , "This is the biggest study that,s ever ...
... Oct. 24 Thelen Reid Brown Raysman &,Steiner ... group has,successfully assisted long-time client The Doctors Company ... major provider of healthcare liability,insurance, for an aggregate ... share in cash. (Logo: http://www.newscom.com/cgi-bin/prnh/20071016/AQTU238LOGO ) ...
... trend, PHILADELPHIA, Oct. 24 Governor Edward ... Reduction of Error,Fund (Mcare) claims have dropped by ... result of reforms, more insurers are writing malpractice ... when it comes to medical malpractice,",Governor Rendell said ...
Cached Medicine News:Health News:Kerry, Snowe Push Finance Committee on Small Business Health Care 2Health News:Kerry, Snowe Push Finance Committee on Small Business Health Care 3Health News:Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent 2Health News:NIEHS awards outstanding new environmental scientists 2Health News:Drink or Two a Day May Help Lungs 2Health News:Drink or Two a Day May Help Lungs 3Health News:Drink or Two a Day May Help Lungs 4Health News:Thelen Assists The Doctors Company in Acquisition of SCPIE Holdings Inc. 2Health News:Governor Rendell Says Mcare Claims and Costs Are 50 Percent Lower Than in 2003 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: